NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments.

On Jan 27, 2016, the National Institute of Health and Care Excellence (NICE) published guidance 1 NICETechnology appraisal guidance TA380. Panobinostat for treating multiple myeloma after at least 2 previous treatments. http://www.nice.org.uk/guidance/TA380 Google Scholar recommending panobinostat in combination with bortezomib and dexamethasone as an option for adults with relapsed or relapsed and refractory multiple myeloma who have received at least two previous regimens, including bortezomib and an immunomodulatory agent, if the company provides panobinostat with the discount agreed in the patient access scheme.